Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, and AnHeart Therapeutics Ltd. (AnHeart), a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer, announce that the companies have entered into a definitive agreement for Nuvation Bio to acquire AnHeart in an all-stock transaction (the Acquisition). Immediately following the closing of the Acquisition, the former shareholders of AnHeart will own approximately 33% and the current stockholders of Nuvation Bio will own approximately 67% of Nuvation Bio on a fully diluted basis.
Read the full article: Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction //
Source: https://www.businesswire.com/news/home/20240325982081/en/Nuvation-Bio-to-Acquire-AnHeart-Therapeutics-in-All-Stock-Transaction